Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trial While Commercializing unbuzzd

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is making strides in both clinical and commercial arenas, as detailed by Executive Co-Chairman and Co-Founder Anthony Durkacz in a recent BioMedWire Podcast. The company's lead drug candidate, Lucid-MS, targets mobility damage in multiple sclerosis (MS) and has reached a critical milestone with the filing of an investigational new drug application for a Phase 2 clinical trial. This trial could mark the first administration of Lucid-MS to human MS patients, moving beyond preclinical models where it has shown promise in preventing and reversing myelin degradation, the underlying cause of MS.

Durkacz emphasized the dual strategy of combining pharmaceutical development with commercial products like unbuzzd, a supplement designed to accelerate alcohol metabolism. Quantum BioPharma retains a 19.84% ownership stake in Unbuzzd Wellness Inc. (UWI), which markets the over-the-counter version, and receives royalty payments of 7% on sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. This structure provides ongoing revenue that supports the company's clinical pipeline.

The company's focus on neurodegenerative and metabolic disorders, along with alcohol misuse, is central to its mission. Lucid-MS, developed through subsidiary Lucid Psycheceuticals Inc., is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical studies. The upcoming Phase 2 trial represents a significant step toward validating these effects in humans.

Quantum BioPharma's broader strategy involves leveraging its commercial success to fund clinical development. The unbuzzd product, now available through UWI, generates royalty income and demonstrates the company's ability to bring products to market. Durkacz highlighted the importance of this commercial opportunity in the podcast, noting that it provides a revenue stream while the company advances its pharmaceutical candidates.

For more details on Quantum BioPharma's strategy and developments, the full podcast and article are available at https://ibn.fm/IWnPQ. Additional news and updates on QNTM can be found in the company's newsroom at https://ibn.fm/QNTM.